BD Board Declares Increased Dividend for 54th Consecutive Year
The Board of Directors at BD (Becton, Dickinson and Company) has announced a quarterly dividend of $1.05 per common share. This decision reflects a slight increase of 1.0% from the prior quarter, showing BD's ongoing commitment to its shareholders. With a record date set for holders on December 8, 2025, the dividend will be paid on December 31, 2025, highlighting the company’s robust financial health.
Commitment to Value Creation
As Tom Polen, the chairman, CEO and president, explained, this increase signifies the company's 54th straight year of dividend boosts. BD continues to be part of the S&P 500 Dividend Aristocrats Index, a group of companies recognized for consistently raising their dividends over a significant number of years. This milestone reflects BD's unwavering confidence in its long-term strategy and capacity to deliver real value back to its shareholders.
Strategic Development Initiatives
Even as BD executes strategic initiatives like the Waters RMT transaction, it remains focused on maintaining its dividend growth trajectory. This not only assures shareholders of returns but also validates the company’s commitment to delivering innovative technologies that enhance patient care and operational efficiencies.
About BD: A Global Leader in Medical Technology
BD is recognized as one of the foremost global medical technology firms dedicated to advancing healthcare. The company strives to enhance medical discovery, diagnostic processes, and care delivery systems. With a dedicated workforce of over 70,000 employees, BD develops cutting-edge solutions that support healthcare professionals on the front lines. By collaborating closely with a variety of health organizations worldwide, BD tackles pressing health challenges, working relentlessly to improve outcomes and lower healthcare costs.
BD’s mission is to improve safety and efficiency within the healthcare delivery system. The company has made significant strides in enhancing disease detection capabilities and aiding researchers in the development of innovative diagnostics and therapeutics. Through these collaborative efforts, BD plays a pivotal role in ensuring better health outcomes for patients globally.
Community Engagement and Global Impact
BD understands the importance of engaging with the communities it serves. The company aligns its objectives with the needs of healthcare systems worldwide, focusing on improving access to essential health services. With ongoing partnerships and strategic alliances, BD is well-positioned to make significant contributions towards global health solutions.
Contacts for Media and Investor Relations
For inquiries related to media, please reach out to Fallon McLoughlin, Director of Public Relations, at 201.258.0361. Investors can contact Adam Reiffe, VP of Investor Relations, at 201.847.6927. These contacts can provide additional information regarding BD's initiatives and shareholder strategies.
Frequently Asked Questions
What is BD's recent dividend announcement about?
BD has declared a quarterly dividend of $1.05 per share, marking a 1.0% increase from the previous quarter.
How many years has BD increased its dividends?
BD has increased its dividends for 54 consecutive years, showcasing its commitment to providing shareholder value.
When will the dividend be payable?
The dividend will be payable on December 31, 2025, to shareholders on record as of December 8, 2025.
How does BD support healthcare?
BD focuses on developing innovative medical technologies, improving diagnostics, and enhancing the delivery of healthcare to better support professionals and patients.
Who can I contact for more information about BD?
For media inquiries, contact Fallon McLoughlin, and for investor information, contact Adam Reiffe via the numbers provided.
